{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T19:28:57Z","timestamp":1749324537842,"version":"3.40.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-08777-y","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T02:19:11Z","timestamp":1742350751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-0775","authenticated-orcid":false,"given":"Alexis","family":"Ogdie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soumya M.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah H.","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Elaine","family":"Husni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose U.","family":"Scher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Salomon-Escoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Kay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent A.","family":"Luedders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisa J. Stephens","family":"Shields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-838X","authenticated-orcid":false,"given":"Soumya D.","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinty","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"8777_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017;376:957\u201370.","journal-title":"N Engl J Med"},{"key":"8777_CR2","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700\u201312.","journal-title":"Ann Rheum Dis"},{"key":"8777_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465\u201379.","journal-title":"Nat Rev Rheumatol"},{"key":"8777_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","volume":"47","author":"JF Merola","year":"2017","unstructured":"Merola JF, Lockshin B, Mody EA. Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum. 2017;47:29\u201337.","journal-title":"Semin Arthritis Rheum"},{"key":"8777_CR5","first-page":"S104","volume":"33","author":"P Mease","year":"2015","unstructured":"Mease P. A short history of biological therapy for psoriatic arthritis. Clin Exp Rheumatol. 2015;33:S104\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"8777_CR6","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1115\u201325.","journal-title":"Lancet"},{"key":"8777_CR7","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s40744-021-00337-5","volume":"8","author":"AM Orbai","year":"2021","unstructured":"Orbai AM, Husni ME, Gladman DD, et al. Secukinumab efficacy on psoriatic arthritis GRAPPA-OMERACT core domains in patients with or without prior tumor necrosis factor inhibitor use: Pooled analysis of four Phase 3 studies. Rheumatol Ther. 2021;8:1223\u201340.","journal-title":"Rheumatol Ther"},{"key":"8777_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40744-020-00261-0","volume":"8","author":"AM Orbai","year":"2021","unstructured":"Orbai AM, Gratacos J, Turkiewicz A, et al. Efficacy and safety of ixekizumab in patients with psoriatic arthritis and inadequate response to TNF inhibitors: 3-Year follow-up (SPIRIT-P2). Rheumatol Ther. 2021;8:199\u2013217.","journal-title":"Rheumatol Ther"},{"key":"8777_CR9","unstructured":"Ogdie A, McLean R, Blachley T, et al. The impact of second-line therapeutic on disease control after discontinuation of first line TNF inhibitor in patients with PsA: analysis from the CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry [abstract]. Arthritis Rheumatol. 2022;74 (suppl 9). https:\/\/acrabstracts.org\/abstract\/the-impact-of-second-line-therapeutic-on-disease-control-after-discontinuation-of-first-line-tnf-inhibitor-in-patients-with-psa-analysis-from-the-corevitas-psoriatic-arthritis-spondyloarthritis-regis\/. Accessed 9 Mar 2023."},{"key":"8777_CR10","volume-title":"Package insert","author":"Tremfya","year":"2024","unstructured":"Tremfya. Package insert. Horsham, PA: Janssen Biotech, Inc.; 2024."},{"key":"8777_CR11","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1126\u201336.","journal-title":"Lancet"},{"key":"8777_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","volume":"81","author":"LC Coates","year":"2022","unstructured":"Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022;81:359\u201369.","journal-title":"Ann Rheum Dis"},{"key":"8777_CR13","volume-title":"Package Insert","author":"Simponi","year":"2023","unstructured":"Simponi. Package Insert. Horsham, PA: Janssen Biotech, Inc.; 2023."},{"key":"8777_CR14","doi-asserted-by":"publisher","first-page":"E47","DOI":"10.1503\/cmaj.090523","volume":"180","author":"KE Thorpe","year":"2009","unstructured":"Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ. 2009;180:E47-57.","journal-title":"CMAJ"},{"key":"8777_CR15","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/ard.2009.122259","volume":"69","author":"M Schoels","year":"2010","unstructured":"Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010;69:1441\u20137.","journal-title":"Ann Rheum Dis"},{"key":"8777_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09546634.2013.865009","volume":"26","author":"RG Langley","year":"2015","unstructured":"Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator\u2019s Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26:23\u201331.","journal-title":"J Dermatolog Treat"},{"key":"8777_CR17","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, G\u00f8tzsche PC, et al. SPIRIT 2013 explanation and elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"key":"8777_CR18","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","volume":"75","author":"MM Schoels","year":"2016","unstructured":"Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75:811\u20138.","journal-title":"Ann Rheum Dis"},{"key":"8777_CR19","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.3899\/jrheum.190219","volume":"47","author":"JA Walsh","year":"2020","unstructured":"Walsh JA, Wan MT, Willinger C, et al. Measuring outcomes in psoriatic arthritis: Comparing routine assessment of patient index data and psoriatic arthritis impact of disease. J Rheumatol. 2020;47:1496\u2013505.","journal-title":"J Rheumatol"},{"key":"8777_CR20","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s40744-023-00592-8","volume":"10","author":"PJ Mease","year":"2023","unstructured":"Mease PJ, Gladman DD, Poddubnyy D, et al. Efficacy of guselkumab on axial-related symptoms through up to 2 years in adults with active psoriatic arthritis in the phase 3, randomized, placebo-controlled DISCOVER-2 study. Rheumatol Ther. 2023;10:1637\u201353.","journal-title":"Rheumatol Ther"},{"key":"8777_CR21","doi-asserted-by":"publisher","first-page":"E715","DOI":"10.1016\/S2665-9913(21)00105-3","volume":"3","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Helliwell PS, Gladman DD, et al. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatol. 2021;3:E715\u201323.","journal-title":"Lancet Rheumatol"},{"key":"8777_CR22","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3899\/jrheum.200371","volume":"48","author":"A Ogdie","year":"2021","unstructured":"Ogdie A, Hur P, Liu M, et al. Effect of multidomain disease presentations on patients with psoriatic arthritis in the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry. J Rheumatol. 2021;48:698\u2013706.","journal-title":"J Rheumatol"},{"key":"8777_CR23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59:686\u201391.","journal-title":"Arthritis Rheum"},{"key":"8777_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/annrheumdis-2024-eular.24","volume":"83","author":"D Aletaha","year":"2024","unstructured":"Aletaha D, Merola JF, Sharaf M, et al. A novel composite endpoint including low peripheral joint disease activity state and clear\/almost clear skin in patients with active psoriatic arthritis: post hoc analyses of 2 phase 3 randomized, double-blind, placebo-controlled studies. Ann Rheum Dis. 2024;83:373.","journal-title":"Ann Rheum Dis"},{"key":"8777_CR25","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","volume":"73","author":"L Gossec","year":"2014","unstructured":"Gossec L, de Wit M, Kiltz U, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73:1012\u20139.","journal-title":"Ann Rheum Dis"},{"key":"8777_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"8777_CR27","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/01.mlr.0000258615.42478.55","volume":"45","author":"D Cella","year":"2007","unstructured":"Cella D, Yount S, Rothrock N, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care. 2007;45:S3\u201311.","journal-title":"Med Care"},{"key":"8777_CR28","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","volume":"63","author":"D Cella","year":"2010","unstructured":"Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008. J Clin Epidemiol. 2010;63:1179\u201394.","journal-title":"J Clin Epidemiol"},{"key":"8777_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48\u201353.","journal-title":"Ann Rheum Dis"},{"key":"8777_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.semarthrit.2019.04.001","volume":"49","author":"K Johnson","year":"2019","unstructured":"Johnson K, Ye JY, Chandran V, Gladman DD. A novel role for the psoriatic arthritis impact of disease (PsAID) questionnaire. Semin Arthritis Rheum. 2019;49:241\u20135.","journal-title":"Semin Arthritis Rheum"},{"key":"8777_CR31","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286\u201391.","journal-title":"J Rheumatol"},{"key":"8777_CR32","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor \u03b1 antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976\u201386.","journal-title":"Arthritis Rheum"},{"key":"8777_CR33","volume-title":"Package Insert","author":"Tremfya (EMA)","year":"2022","unstructured":"Tremfya (EMA). Package Insert. Leiden, The Netherlands: Janssen B.V; 2022."},{"key":"8777_CR34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/acr2.11523","volume":"5","author":"CT Ritchlin","year":"2023","unstructured":"Ritchlin CT, Deodhar A, Boehncke WH, et al. Multidomain efficacy and safety of guselkumab through 1 year in patients with active psoriatic arthritis with and without prior tumor necrosis factor inhibitor experience: analysis of the phase 3, randomized, placebo-controlled DISCOVER-1 study. ACR Open Rheumatol. 2023;5:149\u201364.","journal-title":"ACR Open Rheumatol"},{"key":"8777_CR35","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/art.37876","volume":"65","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor \u03b1 inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum. 2013;65:1213\u201323.","journal-title":"Arthritis Rheum"},{"key":"8777_CR36","doi-asserted-by":"publisher","first-page":"e000880","DOI":"10.1136\/rmdopen-2018-000880","volume":"5","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Karki C, Liu M, et al. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry. RMD Open. 2019;5:e000880.","journal-title":"RMD Open"},{"key":"8777_CR37","doi-asserted-by":"crossref","unstructured":"Ogdie A, Merola JF, Mease PJ, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and\/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study. BMC Rheumatol. 2023.","DOI":"10.1186\/s41927-024-00386-7"},{"key":"8777_CR38","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/17512433.2017.1329009","volume":"10","author":"S Mantravadi","year":"2017","unstructured":"Mantravadi S, Ogdie A, Kraft WK. Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Rev Clin Pharmacol. 2017;10:899\u2013910.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"8777_CR39","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/art.27203","volume":"62","author":"HL Ma","year":"2010","unstructured":"Ma HL, Napierata L, Stedman N, et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum. 2010;62:430\u201340.","journal-title":"Arthritis Rheum"},{"key":"8777_CR40","doi-asserted-by":"publisher","first-page":"e001679","DOI":"10.1136\/rmdopen-2021-001679","volume":"7","author":"K Sweet","year":"2021","unstructured":"Sweet K, Song Q, Loza MJ, et al. Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. RMD Open. 2021;7:e001679.","journal-title":"RMD Open"},{"key":"8777_CR41","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13075-023-03125-4","volume":"25","author":"G Schett","year":"2023","unstructured":"Schett G, Chen W, Gao S, et al. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study. Arthritis Res Ther. 2023;25:150.","journal-title":"Arthritis Res Ther"},{"key":"8777_CR42","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1136\/annrheumdis-2022-eular.892","volume":"81","author":"S Siebert","year":"2022","unstructured":"Siebert S, Coates LC, Schett G, et al. Immunological differences between PsA patients who are tumor necrosis factor inhibitor-na\u00efve and who have inadequate response to tumor necrosis factor inhibitors. Ann Rheum Dis. 2022;81:254\u20135.","journal-title":"Ann Rheum Dis"},{"key":"8777_CR43","doi-asserted-by":"publisher","first-page":"i29","DOI":"10.1093\/rheumatology\/kez305","volume":"59","author":"D McGagh","year":"2020","unstructured":"McGagh D, Coates LC. Assessment of the many faces of PsA: single and composite measures in PsA clinical trials. Rheumatology (Oxford). 2020;59:i29\u201336.","journal-title":"Rheumatology (Oxford)"},{"key":"8777_CR44","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727\u201335.","journal-title":"Arthritis Rheum."},{"key":"8777_CR45","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/art.37939","volume":"65","author":"LC Coates","year":"2013","unstructured":"Coates LC, FitzGerald O, Gladman DD, et al. Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease. Arthritis Rheum. 2013;65:1504\u20139.","journal-title":"Arthritis Rheum"},{"key":"8777_CR46","doi-asserted-by":"crossref","unstructured":"Karmacharya P, Stull C, Stephens-Shields A, et al. Responsiveness and minimal clinically important difference in patient-reported outcome measures among patients with psoriatic arthritis. Arthritis Care Res (Hoboken). 2023;75:2182\u20139.","DOI":"10.1002\/acr.25111"},{"key":"8777_CR47","unstructured":"Mease PJ, Gottlieb AB, Mcinnes IB, et al. Achievement of low disease activity\/remission in guselkumab-treated patients with moderately-highly active psoriatic arthritis regardless of baseline characteristics: pooled post-hoc analysis of two phase 3\/randomized studies [abstract]. Congress of Clinical Rheumatology-East Destin, FL. 2024."},{"key":"8777_CR48","doi-asserted-by":"publisher","first-page":"h2147","DOI":"10.1136\/bmj.h2147","volume":"350","author":"K Loudon","year":"2015","unstructured":"Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147.","journal-title":"BMJ"},{"key":"8777_CR49","doi-asserted-by":"crossref","unstructured":"Ogdie A, Husni ME, Bush K, et al. Patient identified treatment goals in psoriatic arthritis: decreasing pain and increasing activity level are high priorities. EULAR 2019 abstract, AB0769 2019;78:1853\u20134.","DOI":"10.1136\/annrheumdis-2019-eular.1660"},{"key":"8777_CR50","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1186\/s13063-022-06589-y","volume":"23","author":"DD Gladman","year":"2022","unstructured":"Gladman DD, Mease PJ, Bird P, et al. Efficacy and safety of guselkumab in biologic-naive patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. Trials. 2022;23:743.","journal-title":"Trials"},{"key":"8777_CR51","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3899\/jrheum.190299","volume":"47","author":"MD George","year":"2020","unstructured":"George MD, Baker JF, Ogdie A. Comparative persistence of methotrexate and tumor necrosis factor inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2020;47:826\u201334.","journal-title":"J Rheumatol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08777-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08777-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08777-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T02:53:49Z","timestamp":1742352829000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08777-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8777"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08777-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"18 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is being conducted in compliance with the Declaration of Helsinki and International Council for Harmonization Guidelines for Good Clinical Practice. The protocol will be approved by each site\u2019s institutional review board. Each study patient must have given written informed consent prior to conducting any study-related procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AO: grant\/research support to the University of Pennsylvania from AbbVie, Janssen, Novartis, and Pfizer and to Forward from Amgen and Bristol Myers Squibb; consultant fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, CorEvitas, Eli Lilly, Gilead, Happify, Janssen, Novartis, Pfizer, and UCB; her husband has received royalties from Novartis. SMR: consultant for, AbbVie, Amgen, Fresnius Kabi, Janssen, Novartis, UCB. SHG: employee University of Pennsylvania School of Medicine). MEH: received consulting fees and\/or honoraria from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Sanofi Genzyme\/Regeneron and UCB (less than $10,000 each). JUS: consultant for AbbVie, Janssen, Kaleido, Novartis, Pfizer, Sanofi, and UCB; received funding for investigator-initiated studies from Janssen, Novartis, and Pfizer. KSE: None. JK: None. BAL: None. AJSS: receives compensation from the American College of Physicians for editorial work, serves on the External Advisory board for the Florida Atlantic University Summer Institute in Biostatistics, received speaker\u2019s honorarium from NYU in 2023, received consultant fees from WilmerHale on behalf of Gilead Sciences in 2022. SDC: employee of and owns stock in Johnson & Johnson. CG: employee of and owns stock in Johnson & Johnson. JAW: received research funding from AbbVie, Merck, and Pfizer; consulting for AbbVie, Eli Lilly, Janssen, Novartis, and UCB. JRC: received grant\/research support from AbbVie, Amgen, Bristol Myers Squibb, CorEvitas, Eli Lilly, Janssen, Myriad, Novartis, Pfizer, Sanofi, UCB, and NIAMS P30AR072583; received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, CorEvitas, Eli Lilly, Janssen, Myriad, Novartis, Pfizer, Sanofi, and UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}